breast cancer

envie a um amigo share this

High insulin levels contribute to the initiation of breast cancer

Type 2 diabetes mellitus (T2DM) and breast cancer are diagnosed in the same individual more frequently than would be expected. The metabolic alterations that occur in T2DM can probably explain this link. However, to date, the studies done have not been sufficient to identify the mechanisms underlying the link between T2DM and breast cancer. It is therefore critical to identify new molecular targets that link T2DM and breast cancer and to develop new therapeutic approaches that prevent and control breast cancer initiation, promotion and progression in patients with T2DM.

Elevados níveis de insulina contribuem para a iniciação do cancro da mama

A diabetes mellitus tipo 2 (DM2) e o cancro de mama são diagnosticadas no mesmo indivíduo com mais frequência do que seria esperado. As alterações metabólicas que ocorrem na DM2 podem provavelmente explicar essa ligação. No entanto, até o momento, os estudos realizados não foram suficientes para identificar os mecanismos subjacentes à ligação entre DM2 e cancro de mama.

HOXB7 overexpression may lead triple-negative breast cancer cells to a less aggressive Phenotype


Simone Aparecida de Bessa Garcia1, Mafalda Araújo1, Tiago Pereira1 and Renata Freitas1,2

HOXB7 overexpression may lead triple-negative breast cancer cells to a less aggressive Phenotype

Os genes HOX codificam proteínas do tipo “factores de transcrição” que são de extrema importância durante o desenvolvimento embrionário. No entanto, parecem ter um papel também relevante na vida pós-embrionária e a desregulação da sua expressão está inúmeras vezes associada à progressão tumoral e à resistência terapêutica manifestada por alguns doentes. O gene HOXB7, em particular, desempenha um papel importante na progressão do cancro de mama de uma forma dependente do subtipo molecular.

Interferon-γ stimulates the ASCT2 transporter in breast cancer cells

Presently, breast cancer constitutes the most prevalent cancer in women worldwide, and about 25% of the women with breast cancer also present type 2 diabetes mellitus (T2DM).The metabolic changes characteristic of T2DM have been associated to a higher incidence and progression, worst prognontics and response to therapy. However, the association between breast cancer and type 2 diabetes are complex and remain to be fully established.

Novel anti-DLL1 antibody with anti-tumor efficacy against breast cancer

Over 70% of breast cancers (BC) are estrogen receptor-positive (ER+). The Notch ligand Delta-like 1 (DLL1) is a key player in ER+ BCs development and aggressiveness and its overexpression are associated with poor prognosis. In this study, Portuguese researchers developed a novel anti-DLL1 antibody that inhibited tumor growth and liver metastases in a xenograft mouse model. The data suggests that anti-DLL1 immunotherapy can be a promising strategy for ER+ BC treatment.

 

Authors and Affiliations:

Novo anticorpo com propriedades anti-tumorais para cancro da mama

Mais de 70% dos cancros da mama são positivos para o recetor de estrogénio (ER+ BC). A expressão elevada da proteína DLL1 nestes tumores está associada a maior agressividade e por conseguinte a pior prognóstico. Neste estudo, investigadores portugueses desenvolveram um anticorpo capaz de impedir a formação de metástases hepáticas em modelos animais xenotransplantados. Este estudo sugere a inibição da proteína DLL1 como uma nova abordagem no tratamento de cancros da mama positivos para o recetor de estrogénio.

 

Autores e afiliações:

Innovation in Breast Cancer symposium – Lisbon edition

Virtual event

 

14-15 October, 2021

 

See more informations here: https://www.doctaforum.org/2021/ibc2021-lisbon/

Innovation in Breast Cancer symposium – Lisbon edition

Virtual event

 

14-15 October, 2021

 

See more informations here: https://www.doctaforum.org/2021/ibc2021-lisbon/

Natural killer cells put breast cancer to sleep

Even after apparently successful treatment of primary tumor, some undetectable tumor cells can persist and cause cancer to eventually come back. These cells spread beyond the primary tumor to other organs of the body, where they lay dormant until awakening into deadly metastases.